A carefully structured intervention combining a strict low-calorie diet with targeted aerobic and resistance exercise can successfully put early-onset type 2 diabetes into remission in more than half of younger adults, according to landmark clinical trial findings. Presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) and published simultaneously in The Lancet Regional Health Americas, the research demonstrates that an intensive lifestyle program enabled 54 percent of participants to achieve diabetes remission within just 24 weeks. This starkly contrasts with the standard medical care group, where only 4 percent reached the same clinical milestone.
The international study was co-led by Professor Kaberi Dasgupta, Director of the Division of General Internal Medicine at McGill University in Montreal, Canada, and Professor Thomas Yates of the University of Leicester in the United Kingdom, alongside a multidisciplinary team of clinical researchers. The findings suggest that integrating specialized physical activity with energy restriction could radically transform treatment paradigms for early-onset type 2 diabetes (EOT2D), defined clinically as a diagnosis occurring in individuals under the age of 45.
Understanding the Growing Threat of Early-Onset Type 2 Diabetes
Type 2 diabetes has traditionally been viewed as a condition predominantly affecting older adults. However, epidemiological trends globally indicate a concerning surge in diagnoses among younger populations. This shift has alarmed public health officials because early-onset type 2 diabetes is frequently characterized by a far more aggressive disease trajectory than its late-onset counterpart.
Patients diagnosed under 45 typically experience a much faster deterioration of blood sugar regulation. Consequently, they face an elevated lifetime risk of developing severe vascular, renal, and neurological complications decades earlier in life, alongside a notably shortened overall life expectancy. Because these individuals must manage the disease for a greater portion of their lives, cumulative exposure to elevated blood glucose levels inflicts profound damage on the cardiovascular system and other major organs.
Medical science has previously established that very-low-energy diets (VLEDs) can successfully reduce circulating blood sugar enough to induce remission in certain populations, allowing patients to discontinue glucose-lowering medications. In clinical terms, diabetes remission is defined as a sustained drop in glycated hemoglobin (HbA1c) levels below the standard diagnostic threshold of 6.5 percent (48 mmol/mol) that persists for at least three months without the aid of diabetes drugs. While remission signifies a temporary or prolonged normalization of blood sugar rather than a permanent cure, it dramatically reduces the risk of long-term complications.
However, prior dietary interventions alone often suffered from limitations, such as significant losses in lean muscle mass alongside fat reduction, which can inadvertently lower metabolic rate and increase the risk of sarcopenia. To address these shortcomings, the research team hypothesized that incorporating a structured, supervised exercise regimen would not only accelerate fat loss and improve cardiovascular fitness but also protect vital muscle tissue during rapid weight reduction.
Chronology and Design of the RESET for Remission Trial
The randomized clinical trial, titled the RESET for Remission study, was conducted across three specialized academic research centers in the United Kingdom and Canada: the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. Recruitment and enrolment took place between September 24, 2021, and June 6, 2025, reflecting a rigorous multi-year effort to evaluate lifestyle medicine in a diverse, multi-ethnic patient cohort.
The trial enrolled a total of 96 adult participants aged 18 to 45 who had been diagnosed with early-onset type 2 diabetes and clinical obesity, but who were not currently dependent on insulin therapy. Of the 96 enrolled individuals, 40 participated in UK centers while 56 participated in Canadian sites. The cohort featured a balanced demographic distribution, comprising 50 participants assigned to the intensive lifestyle intervention group and 46 participants assigned to the standard medical care control group. Baseline characteristics showed a mean participant age of 38 years and a mean baseline body mass index (BMI) of 35.2 kg/m².
The study design was open-label, meaning both patients and investigators were aware of group assignments during the intervention, though the final assessment of the primary clinical outcomes was conducted in a blinded fashion. Following baseline evaluations, participants in the intervention arm initiated a closely monitored, multi-phase clinical protocol.
Comprehensive Dietary and Exercise Protocol
At the very outset of the 24-week program, participants in the intensive intervention group safely discontinued their existing glucose-lowering and blood pressure medications under strict medical supervision, provided they did not exhibit albuminuria—a marker of protein leakage in the urine indicative of underlying kidney damage.
The dietary intervention was structured in distinct phases. For the first 12 weeks, participants adhered to a strict low-calorie intake of 800 to 900 calories per day, maintaining a macronutrient distribution of approximately 30 percent protein, 50 percent carbohydrate, and 20 percent fat. During the initial two weeks of this phase, all daily meals were entirely substituted with specialized nutritional meal-replacement products (Optifast in the UK and ProtiDiet in Canada). From weeks three through 12, participants maintained the exact same caloric restriction but gained greater culinary flexibility, transitioning to a regimen that permitted one conventional meal per day alongside meal replacements, targeted to include 60 to 90 grams of protein, one portion of fruit, and two portions of non-starchy vegetables daily.
Simultaneously, the exercise protocol was integrated into the participants’ routines. During weeks one through 12, the intervention group engaged in supervised aerobic and resistance training sessions twice per week, complemented by one independent exercise session performed on their own each week.
Between weeks 13 and 24, the program shifted from active, rapid weight loss to weight-maintenance strategies. Participants adapted their diets to sustain their newly achieved weight loss while continuing their independent exercise routines. Meanwhile, the control group continued receiving standard diabetes medical care and general lifestyle advice typical of routine clinical practice.
Clinical Findings: Remission Rates and Body Composition Changes
Of the 96 individuals initially randomized into the trial, an impressive 86 participants—representing 90 percent of the total cohort—successfully completed all final assessments at the conclusion of the 24-week study period.
The primary endpoint yielded dramatic results. After 24 weeks, 27 out of the 50 participants in the intensive lifestyle intervention group achieved full diabetes remission, accounting for 54 percent of the cohort. In stark contrast, only two out of the 46 participants in the standard care control group achieved remission, representing roughly 4 percent. When researchers adjusted for relevant statistical variables, participants in the intensive lifestyle program were calculated to be 21 times more likely to achieve diabetes remission than those receiving routine medical management.
Furthermore, physical transformations among the intervention group were profound. Among the 47 intervention participants with complete weight data, average body weight plummeted from a baseline of 100.7 kg down to 92.3 kg, marking an average reduction of 8.4 kg over the six-month period. Conversely, the 43 control participants with available weight data started at an average weight of 103.2 kg and lost a mere 1.2 kg, ending the study at an average of 102.0 kg.
Statistical adjustments revealed that the intervention group lost an average of 7.5 kg more body weight than the control group. Crucially, body composition analyses demonstrated that this differential included an additional 6.6 kg of pure fat mass loss, confirming that the vast majority of weight lost during the program stemmed from reductions in harmful visceral and subcutaneous adipose tissue rather than water weight or vital lean tissue.
Managing Side Effects and Ensuring Safety
Throughout the trial, clinicians closely monitored participants for adverse events. No severe or life-threatening adverse events were attributed directly to the intervention. However, temporary and manageable side effects were predictably more common among individuals following the restrictive low-calorie diet.
At least one mild to moderate adverse event was documented in 43 of the 50 intervention participants, compared to just six of the 46 control participants. The vast majority of these complaints surfaced during the initial weeks of severe caloric restriction and included transient symptoms such as constipation, headaches, dizziness, and fatigue. These symptoms typically resolved naturally as the body adapted to the protocol or were successfully alleviated with the clinical provision of fiber-based laxatives and adequate hydration targets—such as consuming at least two liters of calorie-free fluids daily.
Preserving Muscle Mass During Rapid Weight Loss
A pioneering aspect of the RESET for Remission trial was its deliberate focus on safeguarding muscle mass during a period of aggressive weight reduction. Medical literature has long documented that traditional very-low-calorie diets frequently induce a dual loss of both fat and fat-free mass, which includes skeletal muscle. When individuals inevitably experience weight regain following such diets, the newly acquired weight often disproportionately consists of adipose tissue rather than lean muscle, a phenomenon that can progressively degrade metabolic health and elevate the risk of sarcopenia over time.
By integrating structured resistance training into the core framework of the weight-loss phase, the researchers demonstrated that substantial fat loss can be achieved while actively preserving muscle mass and enhancing overall muscle quality and functional performance.
Reflecting on this critical component of the study, the research authors noted: "Our RESET for Remission study targeted muscle during the intensive weight loss phase through resistance training, and our findings indicate fat-free mass and muscle preservation is achievable with rapid weight loss. Preserving muscle during remission-oriented weight loss may have important implications for long-term metabolic health, physical function, and disease trajectory."
Broader Implications and Future Outlook
The implications of these clinical findings extend far beyond immediate glycemic control. By addressing early-onset type 2 diabetes through an integrated regimen of diet and exercise, clinicians can successfully reverse hyperglycemia, shrink adipose stores, protect lean muscle tissue, improve cardiovascular function, and elevate patient-reported quality of life.
Furthermore, researchers point out that achieving rapid and sustained diabetes remission early in life could prove exceptionally valuable for young adults planning a family, as achieving stable blood sugar prior to and during pregnancy significantly lowers the risk of maternal and fetal complications.
Despite the highly encouraging results, the study authors emphasize that further investigation is essential. Longer-term follow-up studies are required to determine whether participants can successfully sustain their weight loss, muscle retention, and diabetes remission status over years rather than months when returning to unrestricted, real-world environments outside the structured support of a clinical trial.
In their concluding statements, the trial investigators underscored the clinical urgency of translating these findings into widespread practice: "As the prevalence of early-onset type 2 diabetes rises globally, our findings highlight an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions for remission. Our approach may be particularly valuable in those seeking or with potential for pregnancy. It warrants further evaluation in longer term studies in real-world settings."
